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The main purpose of the AD-4/ACE experiment is to establish the feasibility of 
antiproton cancer therapy. We expect the biological effective dose deposited in the Bragg 
peak region for an identical effect in the entrance channel to be significantly higher for 
antiprotons than for protons and carbon ions. This is based on the observation that a small 
but biological significant portion of the annihilation energy is deposited by nuclear recoil 
ions in the vicinity of the annihilation point. As this portion of the energy is deposited by 
heavy ions the biological efficiency is further increased compared to a proton, enhancing 
the overall effect once more. 
 
A first round of experiments conducted in 2003 and 2004 at CERN and at 
TRIUMF using proton and antiproton beams with approximately 50 MeV kinetic energy 
(which translates into a penetration in water of 22 mm) have shown a significant 
enhancement of the biological effective dose ratio (BEDR) between peak and plateau 
regions for beams of antiprotons compared to protons. The findings of these experiments 
have recently been published in Radiotherapy & Oncology (see attached). 
 
After these initial findings we must now ask the question: “What clinical results 
could be expected from antiproton therapy based on these observation?” Currently, the 
only way to give a qualified answer to this question is through performing detailed 
planning studies for a number of specific cases, and then compare these results to the 
equivalent study using X-rays. protons, and antiprotons. For this type of study a precise 
knowledge of both physical dose and biological effects of the antiproton beam is 
required. 
 
2006 Run Period 
 
The 2006 run period concentrated on issues that will positively impact these 
questions. The measurement separated in too distinct groups, dosimetry and biological 
effects, and were performed at a beam energy of 125 MeV. The main reason for 
requesting this higher energy was to achieve a deeper penetration into the target. At 50 
MeV (or 22 mm waterequivalent depth in the target) the effective penetration into the 
biological target (accounting for additional material intercepting the beam before the 
target like beam monitors and entrance windows for the experiment) was only 10 mm. 
The deeper penetration depth allowed a clear separation of the entrance channel and the 
proton-like behaviour of the antiproton beam in this region from the biological impact 
due to the annihilation events near the Bragg peak. Furthermore, the natural straggling in 
the target led to a width of the pristine Bragg peak that was compatible with the 
biological analysis method. This allowed us to generate a data set which can more easily 
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be compared to theoretical model calculations. In addition, the deeper penetration 
allowed a more precise study of the effects of inflight annihilation and enabled us to 
generate a spread-out Bragg peak with a width of 10 mm. Latter has been consistently 
requested by oncologists since a clinically spread-out Bragg peak will alter the Peak to 
Plateau ratio and especially increase the effects in the entrance channel. 
 
The physical dose distributions predicted by Monte Carlo calculations using the 
code FLUKA are shown for both the pristine peak and the spread-out Bragg peak in 
figure 1. 
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Figure 1:  Physical dose distribution for pristine and spread-out Bragg peaks 
calculated by FLUKA for a 125 MeV antiproton beam 
 
In addition to the standard dosimetry measurements using Alanine tablets and 
GAF chromic film we used for the first time a set of ionization chambers provided by the 
DKFZ in Heidelberg. One of the chambers was mounted in front of the water phantom to 
be used as a calibration tool and the second one could be moved axially with the help of a 
precision caliper. We performed an extensive study across the parameter space for the 
operating voltage of these chambers with the intention to look for saturation effects due 
to the high instantaneous dose rate presented by the short duration of the AD beam 
pulses. This analysis is not yet completed but from the raw data we immediately could 
see that these instruments provided the most stable (relative) measurement of the 
incoming beam intensity shot to shot. We are currently working on extracting an absolute 
calibration for the plateau region which would then allow us to use these chambers as an 
absolute dosimetry tool for future studies. In the mean time we can compare the relative 
dose profile of these measurements with the FLUKA calculations and find excellent 
agreement (Figure 2). 
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Figure 2.:  Comparison between FLUKA prediction and measurements using an 
ionization chamber for a pristine peak. Peak height was normalized as 
an absolute calibration of the chamber has not yet been performed. 
 
For the biological measurements we used the exact same methods as in 2003 and 
2004 with the only difference being the length of the gel tubes necessary to accommodate 
the 100 mm effective depth of the Bragg peak in the target. Cell preparation and the 
analysis of the clonogenic survival measurements were performed at the laboratory of 
Brad Wouters at the University of Maastricht. An early analysis has shown that the 
measurement produced reasonable results but a quantitative analysis has not been 
performed yet due to the lack of time since the end of the run at CERN. In addition to the 
standard clonogenic survival measurements we also performed a set of irradiations with 
the spread-out Bragg peak using a human cancer cell line (FaDu) that was used by our 
collaborators from the Department of Clinical Oncology at the University Hospital in 
Aarhus to study genetic expressions following irradiations of cells with a variety of 
radiation types using micro array analysis. The interest in using an antiproton spread-out 
Bragg peak lies in the fact that the mixture of high LET and low LET radiation 
significantly varies across the depth of the Bragg peak from the proximal side to the 
distal edge. Slices of gel material through out the Bragg peak as well as from a location in 
the plateau have been prepared and fixated and the final analysis will be performed when 
the experimental knowledge of the exact location of the Bragg peak has been determined 
from the clonogenic survival studies (the cost of the analysis per slice in the micro array 
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Summary 
 
We have made significant progress in developing the Monte Carlo capability for 
the biological effect of antiprotons and have now several codes available for 
benchmarking purposes. These include SHIELD-HIT, FLUKA, and MCNPX. We plan to 
use our experimental data and results from the benchmarking calculations obtained from 
these different MC codes as input to the local effect model developed at GSI to produce 
the first planning studies of antiproton therapy. In addition we are discussing with the 
GEANT User’s Group the necessary changes to use the latest version of GEANT 
together with the biological modules recently implemented for estimates of physical dose 
and biological effectiveness of antiproton irradiation  
 
The data collected in this run period will assist us in fine tuning our predictive 
capabilities and will guide us in future experiments. Future work will concentrate on the 
following topics: 
 
1. Finalizing our data set for physical and biological dose in the antiproton beam. 
2. Quantitative measurements of biological effects in the immediate surrounding of 
the beam (distal to the Bragg peak and radial penumbra). 
3. Stochastic effect due to high energy, minimum ionizing annihilation products in the 
far field (several centimeters away from the direct beam). 
 
A detailed description of future work can only be given after the complete 
analysis of the latest run has been completed. 
 
Radiotherapy and Oncology xx (2006) xxx–xxx
www.thegreenjournal.com
ARTICLE IN PRESSOriginal articleThe biological effectiveness of antiproton irradiation
Michael H. Holzscheitera, Niels Basslerb,h,i, Nzhde Agazaryanc, Gerd Beyerd,
Ewart Blackmoree, John J. DeMarcoc, Michael Doserf, Ralph E. Durandg, Oliver Hartleyd,
Keisuke S. Iwamotoc, Helge V. Knudsenb, Rolf Landuaf, Carl Maggiorea,
William H. McBridec, Søren Pape Møllerb, Jørgen Petersenh,i, Lloyd D. Skarsgardg,
James B. Smathersc, Timothy D. Solbergc, Ulrik I. Uggerhøjb, Sanja Vranjesk,
H. Rodney Withersc, Michelle Wongg, Bradly G. Woutersj,*
aPbar Labs, LLC, Santa Fe, NM, USA, bDeparment of Physics & Astronomy and ISA, University of Aarhus, Aarhus, Denmark, cDavid Geffen
School of Medicine at UCLA, Los Angeles, CA, USA, dCentre Medicale Universitaire, Geneva, Switzerland, eTRIUMF, Vancouver, BC, Canada,
fCERN, PH Department, Geneva, Switzerland, gBritish Columbia Cancer Research Centre, Vancouver, BC, Canada, hDepartment of Medical
Physics, and iDepartment of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark, jVinca Institute of Nuclear
Sciences, Belgrade, Serbia and Montenegro, kDepartment of Radiation Oncology (Maastro Lab), GROW Research Institute,
University of Maastricht, The NetherlandsAbstract
Background and purpose: Antiprotons travel through tissue in a manner similar to that for protons until they reach the
end of their range where they annihilate and deposit additional energy. This makes them potentially interesting for
radiotherapy. The aim of this study was to conduct the first ever measurements of the biological effectiveness of
antiprotons.
Materials and methods: V79 cells were suspended in a semi-solid matrix and irradiated with 46.7 MeV antiprotons,
48 MeV protons, or 60Co c-rays. Clonogenic survival was determined as a function of depth along the particle beams. Dose
and particle fluence response relationships were constructed from data in the plateau and Bragg peak regions of the
beams and used to assess the biological effectiveness.
Results: Due to uncertainties in antiproton dosimetry we defined a new term, called the biologically effective dose
ratio (BEDR), which compares the response in a minimally spread out Bragg peak (SOBP) to that in the plateau as a
function of particle fluence. This value was 3.75 times larger for antiprotons than for protons. This increase arises due
to the increased dose deposited in the Bragg peak by annihilation and because this dose has a higher relative biological
effectiveness (RBE).
Conclusion: We have produced the first measurements of the biological consequences of antiproton irradiation. These
data substantiate theoretical predictions of the biological effects of antiproton annihilation within the Bragg peak, and
suggest antiprotons warrant further investigation.c 2006 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology xx (2006) xxx–xxx.
Keywords: Antiproton; RBE; Particle irradiation; High LETFor conventional photon irradiation, the maximum dose
that can be delivered to a tumor is limited by the tolerance
of irradiated adjacent normal tissues. Several technological
improvements in radiation delivery, including intensity-
modulated radiotherapy (IMRT), have made it possible to
confine the high-dose region to almost any target volume
of interest and thus reduce the dose to adjacent tissues
[1–3]. However, even with these techniques, normal tissue
tolerances can prevent delivery of a dose sufficient to
achieve tumor cure. IMRT also results in a larger total body0167-8140/$ - see front matter c 2006 Elsevier Ireland Ltd. All rights re
Please cite this article in press as: Holzscheiter MH et al., The biologic
doi:10.1016/j.radonc.2006.09.012exposure and thus an increased risk of secondary cancers
[4]. For many types of tumors, this has led to unacceptably
low tumor control probability (TCP) and to high levels of
morbidity. An alternative approach involves the use of pro-
tons and other heavier ions [5–8]. For these charged parti-
cles, both the amount and rate of energy deposition
increase dramatically as the particle nears the end of its
range. This results in a large enhancement in absorbed dose
at a precise depth in tissue (the Bragg peak) compared with
the dose deposited at the entrance to the body (the pla-served. doi:10.1016/j.radonc.2006.09.012
al eﬀectiveness of antiproton irradiation, Radiother Oncol (2006),
1 BERGOZ Instrumentation, Espace Allondon Ouest, 06130 Saint
Genis Pouilly, France.
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ARTICLE IN PRESSteau). For treatment purposes, the position of the Bragg
peak needs to be spread out to cover the tumor volume
and the production of such a spread-out Bragg peak (SOBP)
results in a build up of plateau dose and hence a reduction in
the ratio of dose in the SOBP relative to the plateau. How-
ever, in contrast to photons, the dose in the SOBP that cov-
ers the tumor volume remains larger than that in the normal
tissue entrance region. High linear energy transfer (LET)
particles such as carbon ions also produce a much higher
ionization density in the Bragg peak region and consequently
an increase in the relative biological effectiveness (RBE) of
the dose deposited in the tumor [9–11]. This provides a po-
tential further therapeutic advantage, especially for tumors
that have a large hypoxic fraction or for those that are
resistant to conventional radiation [12]. Furthermore, since
very little dose is deposited distal to the Bragg peak,
charged particles are ideally suited for treatments of
tumors close to radiosensitive regions. These favorable
physical and biological characteristics have led to recent
developments of proton and heavy ion cancer therapy cen-
ters worldwide.
Conversion of the mass of a proton–antiproton pair dur-
ing annihilation constitutes the highest density energy
source currently available. This has led to a number of pro-
posals for practical applications of antiprotons, including
radiotherapy, which is feasible with current antiproton pro-
duction technology [13]. Like other charged particles, anti-
protons deposit most of their kinetic energy near the end of
their path in the Bragg peak. In addition, as an antiproton
comes to rest it annihilates, depositing additional energy
in the form of particles that may have a significantly
enhanced biological effectiveness [14]. The majority of
the total annihilation energy of 1.88 GeV is carried away
by high-energy pions, neutrons and c-rays. We have estimat-
ed (unpublished data) that the dose deposition from these
particles is of a similar magnitude to that reported for a pas-
sively degraded proton beam [4]. However, at the Bragg
peak it has been estimated that antiprotons deposit an addi-
tional 30 MeV within a few millimeters of the annihilation
vertex [15]. The only experimental data relevant to the
application of antiprotons for biological purposes were pro-
duced by Sullivan [16], who measured the relative physical
dose deposition in the plateau and the Bragg peak regions
for antiprotons at the low energy antiproton ring (LEAR) at
CERN. He found that although the additional local dose
deposited is small compared to the total annihilation ener-
gy, it does represent an approximate doubling of the physi-
cal dose deposited per particle in the Bragg peak compared
to protons. Furthermore, the RBE of this additional dose is
likely to be significantly higher than that for protons be-
cause it is due partly to recoiling heavy fragments produced
in the annihilation event with short range and high LET. The
remainder of the annihilation energy that is carried
away,outside of the body, could potentially be used for
real-time imaging of the dose distribution.
To date there has been no attempt to assess the biolog-
ical effects of antiprotons. This stimulated us to initiate an
experiment, AD-4/ACE [17,18], running at the antiproton
decelerator (AD) at CERN, to measure the biological effects
of antiproton irradiation and compare it to the results
achievable with protons.Please cite this article in press as: Holzscheiter MH et al., The biologic
doi:10.1016/j.radonc.2006.09.012Materials and methods
Beam characteristics
The AD at CERN delivered a 200–500 ns beam pulse con-
taining approximately 3 · 107 antiprotons every 85 s. For our
experiment the extraction energy was 46.7 MeV. In order to
spread the Bragg peak we used a ridge filter consisting of a
plastic sheet machined with a matrix of pixels 1 mm2 in
area. Three pixel thicknesses (1, 1.8 and 2.6 mm) were used
at a ratio of 41:31:28 to create a SOBP as smooth as possible
over a distance of slightly more than 2.5 mm. The degrader
was placed 25 cm upstream of the target so that the lateral
straggling together with the free drift in air would remove
any radial dose inhomogeneity from the degrader in the
samples. A schematic of the set-up is shown in Fig. 1.
For proton irradiation, we utilized the treatment facility
located at TRIUMF, details of which have been previously
published [19]. The energy was reduced to 48 MeV with a
range shifter to closely match the energy of the antiproton
beam. The proton Bragg peak was also spread out over an
area slightly larger than 2.5 mm using a two-step rotating
wedge filter in order to create a dose profile which matched
that of the antiproton as close as possible.
For 60Co irradiation, a Theratron unit at the Vancouver
Cancer Centre was used as described previously [19].
Dosimetry
Due to the pulsed nature of the antiproton beam it was
not possible to use currently available dosimetry equipment
to measure absorbed dose. The large number of antiprotons
delivered in such a short period of time leads to saturation,
non-linearity and unreliability of conventional equipment
such as ionization chambers. Thus, in order to estimate
the absorbed dose and the relative depth dose profile we
carried out a Monte Carlo simulation based on measure-
ments of antiproton fluence using the MCNPX code [20].
Antiproton fluence was monitored using two independent
methods. After the ridge filter the antiproton beam passed
through a current monitor (Bergoz1 BCM/ICT) capable of
integrating a pulse with rise times as short as a few picosec-
onds without significant loss. The voltage was then held
level for about 400 ls for read-out. The signal processor
used two integrating windows to correct for baseline noise
and therefore achieved high accuracy for low beam current.
In our set-up the sensitivity was 1 mV/6.3 · 105 antiprotons,
resulting in a typical read-out of 50 mV per pulse. The noise
was less than 5 mV, allowing a fluence measurement to
within 10%. We also received a signature from the acceler-
ator on the number of antiprotons having left the ring upon
ejection, which was typically within 20% of the ICT mea-
surement indicating a high-transfer efficiency to our
experiment.
In order to estimate the dose with Monte Carlo methods,
it was also necessary to determine the radial-beam profile,
and thus the fraction of antiprotons that enter the biologi-
cal sample. We monitored the integrated beam profile using
GAF chromic film, which darkens in a linear way with dose.
Because the sensitivity is low, it was necessary to integrateal eﬀectiveness of antiproton irradiation, Radiother Oncol (2006),
Fig. 1. Schematic set-up of the antiproton experiment. The antiproton beam leaves the accelerator vacuum through a thin titanium window,
passes through a two-step ridge filter, a beam current monitor and a scintillator before entering a plexiglass tank containing a glycol/water
mixture and the biological sample (see photo inset upper right). Also shown are the antiproton dose profile and the slicing protocol for
extracting cell survival data after the irradiation.
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system consisting of a thin sheet of BC-400 scintillator
material intercepting the beam without affecting energy
or straggling significantly. This material was placed near
the entrance to the phantom and viewed by a sensitive
CCD camera.2 To reduce noise, the camera was synchro-
nized with the arrival of the pulse, and the signal was suffi-
cient to obtain the beam profile and to determine the
centroid and diameter of a single shot from the AD. This
system also allowed us to adjust the beam position in sub-
millimeter increments. Only the central part of the Gauss-
ian-shaped beam was used to ensure a radial variation of
less than 5%.
For protons, the delivered dose was measured by a cali-
brated transmission chamber and relative depth–dose mea-
surements were carried out with a parallel plate ionization
chamber.2 APOGEE Instruments Inc., KX1E Digital Imaging System, com-
prising a TE cooled camera head with Grade 2 Kodak KAF-0401E
CCD.
Please cite this article in press as: Holzscheiter MH et al., The biologic
doi:10.1016/j.radonc.2006.09.012Measurement of clonogenic survival
We chose to use V79-WNRE cells in these studies because
this cell line has been used previously to quantify the biolog-
ical characteristics of other particle beams [19]. We em-
ployed a modified form of the sliced-gel technique of
Skarsgard and co-workers [19,21] coupledwith the cell sorter
survival assay, details of which are published elsewhere
[19,22]. Briefly, cells were cultured in MEM supplemented
with 10% fetal bovine serum and maintained in exponential
growth. Cells were harvested with trypsin, and re-suspended
at 2 · 106 cells/ml in MEM containing 20% FBS and 12% gelatin
(gel/medium). At 37 C, this was a viscous fluid and for proton
and antiproton irradiations, was poured into ABS (acryloni-
trile butadiene styrene) plastic tubes of 0.6 cm inside diame-
ter and 18 cm length, with a piston located so as to
accommodate a 6-cm deep cylinder of gel/medium. For
60Co irradiation, 0.5–1 ml samples of the cell/gel suspension
were deposited into 5 ml plastic test tubes. After solidifica-
tion at 4 C the tubes were sealed and stored on ice.
For irradiation, sample tubes were placed with their axis
collinear with the beam axis, in a circulating, refrigerated
bath containing a 19.3% glycerol/water solution. The densi-al eﬀectiveness of antiproton irradiation, Radiother Oncol (2006),
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medium, glycerol/water) were carefully chosen to produce
identical stopping powers throughout the entire phantom.
The cells were maintained at 2 C throughout the irradiation
procedure and were kept on ice prior and subsequent to
irradiation. This maintained the spatial organization of the
cells, and also avoided dose-rate effects that would have
otherwise confounded measurements (individual sample
antiproton exposures were as long as 16 h). Only the central
part of the antiproton beam was used to irradiate the cell
sample tube, thus assuring an intensity variation across
the sample of less than 5%. After irradiation, the gel was
extruded from the tube and cut into slices of 0.5 or 1 mm
thickness. These slices were melted in warm culture medi-
um and a cell sorter was then used to sort an accurately
known number of cells from each sample. Two to three sorts
from each slice were plated into individual 100-mm Petri
dishes with 14 ml of culture media and allowed to form col-
onies (defined as >50 cells) for 6–7 days. A sufficient num-
ber of cells was plated to produce 400–500 colonies per
dish. Three slices upstream of the SOBP which received zero
primary dose were used to measure the plating efficiency
(PE).
For comparison purposes we also measured the clonogen-
ic survival response of V79 cells in the gelatin-matrix to 60Co
irradiation. This served as both a reference to measure the
RBE for protons and also allowed us to control for any minor
variations in the radiosensitivity of the cells between exper-
iments. For antiproton experiments, samples were prepared
at CERN and irradiated in Vancouver after transport. For
proton experiments, 60Co samples were irradiated at times
similar to the proton samples.
Determination of RBE and BEDR
The goal of our experiments was to obtain an estimate of
the biological effect of antiprotons. Conventionally, this
property would be the RBE, which is equal to the ratio of
absorbed dose between the conventional and test irradia-
tion producing the same level of survival. For proton irradi-
ation it was possible to determine RBE because we have a
reliable measure of dose. RBE was calculated as the ratio
of 60Co to proton doses which resulted in the same level
of cell survival. Dose values were determined from linear
quadratic (LQ) fits to the survival data.
It was not possible to calculate a similar RBE for antipro-
tons because we did not have a reliable measure of the
absorbed dose. Thus, it was necessary to design compara-
tive experiments in such a way that measurement of abso-
lute dose was not required. To do this we compared
survival responses obtained in the SOBP with those obtained
in the plateau following delivery of a known number of par-
ticles (fluence). Because the dose in the plateau and the
SOBP are directly proportional to the fluence, it is possible
to compare the responses without knowing the conversion
factor from fluence to dose. We defined a new term called
the biologically effective dose ratio (BEDR), equal to the ra-
tio of plateau to SOBP fluences required to produce a de-
fined level of survival.
BEDR ¼ Fluenceplateau
Fluencepeak
;Please cite this article in press as: Holzscheiter MH et al., The biologic
doi:10.1016/j.radonc.2006.09.012where Fluenceplateau and Fluencepeak are the different flu-
ences that produce the same level of cell survival. It can
be shown that BEDR is numerically equal to
BEDR ¼ F RBEpeak
RBEplateau
;
where F is the ratio of the physical dose deposited in the
SOBP to that deposited in the plateau.Results
Physical dose
The axial physical dose profiles of the proton and anti-
proton beams are shown in Fig. 2. For protons, this figure
represents the measured relative dose as a function of
depth in water and for antiprotons it is a Monte Carlo esti-
mate based on conversion from particle fluence measure-
ments. The modulation of dose in the Bragg peak results
from the use of the discrete two-step degrader with a step
size comparable to the width of the pristine Bragg peak for
this energy. As expected, the peak to plateau dose ratio is
much larger for antiprotons than for protons. Defining a
point 7 mm upstream as the plateau yields a measured
dose ratio of 2.0 for protons and an estimated 4.0 for anti-
protons. The positions and widths of gel slices used to
measure clonogenic survival in different regions of the
beam are also shown.
Because samples were irradiated over a 24-h period at
CERN and then transported to Vancouver, the cells were
maintained in gel at cold temperatures for 42–54 h. The
PE measured from each sample tube, as well as the PE from
several unirradiated controls allowed us to monitor the con-
sequences of this exposure (see Fig. 3a). Although, there
was a small trend towards increased toxicity with time (a
drop in PE from 0.7–0.6), the PE remained high through-
out the experiment and comparable to that measured previ-
ously[19]. Fig. 3b shows the 60Co survival curves determined
during both the proton experiment at TRIUMF and the anti-
proton experiment in CERN. The similarity of these two
responses also indicates that the long exposure to gel did
not significantly affect radiosensitivity.
Survival data
Fig. 4a and b show the clonogenic survival determined
from individual gel slices plotted as a function of depth
throughout the proton and antiproton beams. The depth in
gel has been converted to its stopping-power equivalent
depth in water. All material in front of the gel (the gel
cap, tank window, and other materials) has also been con-
verted to water equivalent depth and included so that the
plots represent the total particle range.
For the proton experiment, cell survival was determined
from 20 individual slices as a function of depth in each of
eight sample tubes receiving a different dose to the SOBP.
The dose range to the SOBP was 1–14Gy and resulted in sur-
vival measurements over 1 log in both the peak and plateau
regions. The survival responses are in good agreement with
expectations from the measured dose distributions shown in
the upper panel. The steep dose gradient beyond the edgeal eﬀectiveness of antiproton irradiation, Radiother Oncol (2006),
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Fig. 2. Physical dose profiles and slicing protocol. The measured physical dose along the axis of the range-modulated proton beam at TRIUMF
(a) and the Monte Carlo estimated physical dose along the axis of the range-modulated antiproton beam at CERN (b) are shown as a function of
depth in water. The SOBP is approximately 2.5 mm in width. Also plotted are the positions and widths of gel slices from which clonogenic
survival was determined. Four positions in the peak (2 mm total width), and two positions 7 mm upstream from the peak center (2 mm total
width) were used to determine average values for the SOBP and plateau, respectively (shaded areas). Three slices beyond the Bragg peak were
used to determine plating efficiency.
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Fig. 3. Plating efficiency and radiosensitivity during extended exposure to gelatin. The plating efficiency of V79-WNRE cells as a function of
time at 0 C in the gelatin matrix from samples used during one of the antiproton experiments (a). Plating efficiency was determined from
individual sample tubes that received antiproton irradiation (p), or from untreated control tubes (control). Plating efficiencies of the 60Co
control samples are also shown (60Co). The clonogenic survival of V79-WNRE cells is shown as a function of 60Co dose (b). These 60Co-response
curves were derived from samples prepared during the antiproton experiment at CERN (p) and during the proton experiment at TRIUMF (p+).
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ple tube to less than 0.5 mm.
Fig. 4b shows similar data obtained following irradiation
with antiprotons. Because it was not possible to measure
absolute dose, we used the estimates based on measured
antiproton fluence and Monte Carlo models. Survival data
were determined at 23 positions in depth for six individual
sample tubes irradiated with estimated peak doses between
1 and 25Gy. These data demonstrate a much higher differ-
ence between the peak and plateau regions. Interestingly,Please cite this article in press as: Holzscheiter MH et al., The biologic
doi:10.1016/j.radonc.2006.09.012the non-uniform dose in the SOBP predicted by Monte Carlo
analysis is reflected in these measurements.
RBE and BEDR
In Fig. 5a, we have plotted the survival as a function of
absorbed dose for both proton and 60Co irradiation. The pro-
ton dose responses were constructed from the data shown in
Fig. 4a. The survival in the peak region was calculated from
the average of the four 0.5 mm slices located within the
SOBP and the survival in the plateau was calculated as theal eﬀectiveness of antiproton irradiation, Radiother Oncol (2006),





































































Fig. 4. Clonogenic survival response to antiprotons and protons. The clonogenic survival of V79-WNRE cells is plotted as a function of water
equivalent depth along the axis of the proton beam (a) and antiproton beam (b). Survival was measured in 20 individual gel slices after proton
irradiation and in 23 slices after antiproton irradiation in individual tubes irradiated with a range of peak doses. Each line represents a single
tube irradiated with the measured proton (a) or estimated antiproton (b) dose to the SOBP. For reference, the physical dose profiles are shown
in the upper frames.
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Fig. 2a). The relative dose in the plateau at this point was
51% of that in the peak. The resulting dose response in
the plateau is indistinguishable from that for 60Co irradia-
tion, and thus the RBE in this region is 1. The radiation sen-
sitivity of cells irradiated in the SOBP is significantly higher.
We used the LQ model to fit the 60Co and proton SOBP
responses and then calculated the RBE at different levels
of survival (Fig. 5a). The RBE20 (RBE at a surviving fraction
of 20%) for the proton SOBP is equal to 1.2, in good agree-
ment with previous measurements with this system [19].
In Fig. 5b and c, we have replotted the plateau and SOBP
survival as a function of particle fluence rather than ab-
sorbed dose. In this manner, the response in the SOBP ap-
pears far more sensitive than in the plateau (compare
proton data in Fig. 5a and b). This arises because the ab-
sorbed dose per particle in the SOBP is higher (for protons
2-fold) and additionally because the RBE in the SOPB is
higher. These fluence based survival responses were then
fit using the LQ equation, and the resulting parameters used
to calculate the BEDR. This value is equal to the ratio of flu-
ences in the plateau and the peak that give the same level
of cell survival. At 20% survival the BEDR for protons is 2.4.
The survival responses in the SOBP and plateau regions of
the antiproton beam are shown as a function of fluence in
Fig. 5c. These plateau data were calculated as the average
survival from two 1 mm slices located 7 mm upstream of the
SOBP, and the SOBP response is taken from the average of
the four 0.5 mm slices located within the SOBP region. Data
extracted from the data set shown in Fig. 4b are labeled as
Exp1. Also shown in Fig. 5c, are data obtained from a small-Please cite this article in press as: Holzscheiter MH et al., The biologic
doi:10.1016/j.radonc.2006.09.012er experiment carried out 3 months prior (Exp 2). The BEDR
for antiprotons determined from LQ fits to these data is
shown in the lower frame of Fig. 5c. At 20% survival the anti-
proton BEDR is equal to 9.0, or about 3.75 times higher than
for protons.
Antiproton RBE
Although, we could not directly measure antiproton RBE,
it is possible to make an estimate of this value based on the
measurements presented so far. The ratio of BEDR for anti-


















The only value in this equation that has not been estimated
or measured is the antiproton RBE in the plateau. However,
this value is equivalent to the proton plateau RBE provided
that in-fight annihilation dose is insignificant. We estimated
the consequence of in-flight annihilation by finding an accu-
rate universal fit to all measured annihilation cross sections
known to us, from which we calculated the effect in our
specific case [23]. Using our knowledge of the stopping
power of antiprotons we then calculated the number of
remaining antiprotons, and the electronic energy deposited
along the beam path (Fig. 6a). Here, we have ignored elastical eﬀectiveness of antiproton irradiation, Radiother Oncol (2006),
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Fig. 5. Determination of RBE and BEDR. The average survival of cells within the SOBP and plateau region of the proton beam are plotted as a
function of absorbed dose (a, upper frame). These data were fit with the LQ model, and the resulting parameters used to calculate the RBE as a
function of surviving fraction (a, lower frame). In (b), the same proton data from (a) are plotted as a function of proton fluence (upper frame)
and fits to these data were used to calculate the BEDR (lower frame). In (c, upper frame), the average survival of cells within the SOBP and
plateau region of the antiproton beam are plotted as a function of antiproton fluence. Fits to these data were used to calculate the antiproton
BEDR (c, lower frame). In the text, BEDR and RBE values are quoted at a survival of 20%. At this level of survival, the BEDR for antiprotons is
approximately 3.75-fold higher than for protons due to the increased annihilation dose in the SOBP and its higher RBE.
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a b
Fig. 6. Estimation of RBE in the antiproton SOBP. The amount of deposited energy along the tracks of 50, 120 and 250 MeV antiprotons passing
through water (dashed lines) (a). Also shown in this plot are the remaining fractions of antiprotons for each of these energies (solid curves). In
(b) the RBE in the antiproton SOBP has been estimated for different values of the peak to plateau dose ratio. The product of the RBE and this
ratio is equal to the measured BEDR. The shaded area represents the best estimate for the dose ratio.
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sumed that each annihilation deposits 30 MeV of energy
locally. The loss of antiprotons with an initial energy ofPlease cite this article in press as: Holzscheiter MH et al., The biologic
doi:10.1016/j.radonc.2006.09.01250 MeV due to in-flight annihilation is very small (8%) and
even for higher energies up to a depth of 40 cm, a distinct
Bragg peak remains.al eﬀectiveness of antiproton irradiation, Radiother Oncol (2006),
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The only value that has not been directly measured in this
equation is the dose ratio (F) for antiprotons. However, if
we use the Monte Carlo estimate of 4.0 for this value as
depicted in Fig. 2b, the antiproton RBE in the SOBP is equal
to 2.25. Because we are not completely certain of the Monte
Carlo dose estimates we have also plotted in Fig. 6b the
relationship between F and the peak RBE for antiprotons
that is required to produce the measured BEDR20 value of
9.0.Discussion
The biological effectiveness of antiprotons
The data presented here are the first measurements to
date of the biological consequences of antiproton irradia-
tion. The nature of the antiproton beam made it impossible
to determine standard dose–response curves that could be
compared with low-LET radiation to determine the RBE. We
thus defined the BEDR, a new term that is based on compar-
ing the responses in the peak and plateau regions as a
function of particle fluence. This value is biologically mean-
ingful, because it represents a direct measurement of the
gain in ‘biologically equivalent dose’ deposited in the Bragg
peak region compared to that in the plateau. Since the dose
deposition in the plateau is essentially identical for proton
and antiproton beams of similar energy, a comparison of
the BEDR of protons with that of antiprotons provides a di-
rect measure of the additional biological consequences of
annihilation events at the Bragg peak.
At 20% survival the BEDR20 for antiprotons was equal to
9.0 and for protons it was 2.4- or 3.75-fold lower. The
BEDR for antiprotons increased because of two factors:
(i) the increase in the ratio of dose deposited in the SOBP
relative to the plateau due to the annihilation dose and (ii)
the increase in the RBE of the extra annihilation dose. For
protons, the RBE in the SOBP was 1.2 and the peak to pla-
teau dose ratio was 2.0. The product of these two values
gives the BEDR value of 2.4. For antiprotons our best esti-
mate of the peak to plateau dose ratio is 4.0-, or 2-fold
higher than that for protons. This results in an estimate
of the antiproton SOBP RBE of approximately 2.25 provided
that the RBE in the plateau region is similar to that for
protons. Our estimation of in-flight annihilation dose indi-
cates that this effect is indeed small, suggesting that this
assumption is valid. Given the fact that the annihilation
dose in the peak accounts for only an estimated 50% of
the total dose in this area, an average RBE of 2.25 in this
region implies that the RBE for the dose contributed by
annihilation must be very high.
Comparison to carbon ions
It would be interesting to compare our measurements
with other high LET particles, such as carbon ions. Blakely
et al. [9] measured cell survival in pristine peaks ofPlease cite this article in press as: Holzscheiter MH et al., The biologic
doi:10.1016/j.radonc.2006.09.012400 MeV/u carbon ions using the Berkeley Bevalac. Range
straggling in this high-energy beam yielded a Bragg peak
of stopping width similar to our modulated proton and anti-
proton beams (3 mm at 80% of maximum). We estimated
the BEDR for this carbon ion beam to be 7.9, using a defini-
tion for the plateau point reflecting the situation encoun-
tered at CERN (7 mm upstream). However, the much
greater range of the carbon ions adds uncertainty to this
estimate. Because the gradient on the proximal side of
the Bragg peak changes drastically with penetration depth,
it is difficult to make a proper choice for the plateau defini-
tion. Weyrather et al. [10,11] have also reported RBE values
for a range of carbon ion energies. Using SRIM [24] we calcu-
lated a dose profile for a pristine carbon beam with a range
equivalent to our set-up at CERN and estimated the maxi-
mum BEDR from the Weyrather data to be 8.5 (after cor-
recting for the loss of primary ions due to fragmentation).
This result is for an unmodulated pristine Bragg peak.
Spreading the Bragg peak to a width similar to that in our
experiment significantly lowers the peak to plateau-dose
ratio and hence the BEDR. We estimated this would reduce
the BEDR to 5. High uncertainties in this analysis have
prompted us to begin a comparison measurement for carbon
ions using a set-up equivalent to that at CERN.
Another important consideration in the comparison of
antiproton irradiation with other high-LET particles is the
value of the RBE upstream of the Bragg peak. As discussed
above, the RBE for antiprotons in the plateau region is not
expected to be different from that for protons. Because
the contribution of in-flight annihilation is small, the biolog-
ical dose deposited outside of the Bragg peak per particle is
essentially the same as that for a proton. This would have a
significant clinical advantage over other high LET particles
such as carbon ions, which have RBE values significantly
greater than 1 in the plateau region of the depth-dose
curve. As a consequence, it is not possible to use the clinical
experience with low-LET radiations to estimate normal tis-
sue tolerances without making an assumption for the RBE.
Because high-LET particles often have RBE values that are
energy, dose and cell type specific, one must use caution
in the application of these particles in the clinic. For anti-
protons, because the annihilation dose (high-LET compo-
nent) would be confined to the tumor, it would be
possible to treat using established normal tissue dose
tolerances.Peripheral damage
An important aspect for any new irradiation concerns the
biological consequences of dose that may be deposited out-
side of the primary beam. Initial attempts to assess periph-
eral damage caused by antiproton annihilation suggest it is
quite small. Even for the highest dose used in our experi-
ments, which resulted in a surviving fraction of 20% in the
plateau, we observed 55% survival at only 2 mm distal to
the Bragg peak (see Fig. 3). Furthermore, we also made pre-
liminary measurements of clonogenic survival in sample
tubes placed perpendicular to the beam at the Bragg peak.
These data also indicate that the peripheral dose is small
(data not shown). Further experimental studies in the
peripheral regions using beams with peaks spread accordingal eﬀectiveness of antiproton irradiation, Radiother Oncol (2006),
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tify these effects.Conclusion
In conclusion, our experiment has produced the first di-
rect measurements of the biological consequences of anti-
proton irradiation. It substantiates theoretical predictions
and earlier speculations on the consequences of antiproton
annihilation within the Bragg peak [15,25]. For the beams
compared in our study, the BEDR for antiprotons was 3.75-
fold larger than the BEDR for protons, which represents a
substantial increase in effective dose within the SOBP. In
a treatment situation, a higher energy beam with a larger
SOBP would be required to treat tumors of a reasonable
size. As a result, the peak to plateau dose ratio for either
a proton or antiproton beam would be significantly reduced,
and the comparison would yield a value below the value ob-
served here. However, antiprotons would retain a signifi-
cant biological dose advantage due to the contribution of
both the annihilation dose and its high estimated RBE. In
this regard, it is important to note that there are a number
of treatment situations in which increases in tumor dose as
small as 10–20% can produce significant improvements in
outcome.
Future research has to show if the advantages of antipro-
tons in terms of (a) higher physical dose in the Bragg peak,
(b) the increased RBE confined to the Bragg peak and (c) the
real-time imaging capability will warrant their serious con-
sideration as an alternative modality for tumor irradiation.
At that time it will be necessary to analyze both the techni-
cal and financial problems posed by the antiproton produc-
tion process. While the actual treatment center will be
similar to a standard proton center, the production of anti-
protons requires accelerating protons to 20–30 GeV. With
current technology this requires a synchrotron of about
100–200 m in diameter. Production, capture, storage and
delivery of antiprotons will require a number of additional
accelerator rings. CERN currently produces a modest
amount of antiprotons that suffice for limited biological
studies. GSI is planning the construction of a high energy
addition to their existing facility which will make available
antiprotons useful for irradiation at greater depths at inten-
sities sufficient for standard irradiation times and realistic
tumor volumes [26]. This facility could theoretically be used
to further evaluate and develop antiproton treatment
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